PT3982960T - Tratamentos do angioedema hereditário - Google Patents

Tratamentos do angioedema hereditário

Info

Publication number
PT3982960T
PT3982960T PT207342833T PT20734283T PT3982960T PT 3982960 T PT3982960 T PT 3982960T PT 207342833 T PT207342833 T PT 207342833T PT 20734283 T PT20734283 T PT 20734283T PT 3982960 T PT3982960 T PT 3982960T
Authority
PT
Portugal
Prior art keywords
treatments
hereditary angioedema
angioedema
hereditary
Prior art date
Application number
PT207342833T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of PT3982960T publication Critical patent/PT3982960T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
PT207342833T 2019-06-14 2020-06-15 Tratamentos do angioedema hereditário PT3982960T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema

Publications (1)

Publication Number Publication Date
PT3982960T true PT3982960T (pt) 2023-09-26

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207342833T PT3982960T (pt) 2019-06-14 2020-06-15 Tratamentos do angioedema hereditário

Country Status (34)

Country Link
US (1) US20220218680A1 (enExample)
EP (2) EP3982960B1 (enExample)
JP (3) JP7356518B2 (enExample)
KR (1) KR102748728B1 (enExample)
CN (1) CN114126612A (enExample)
AR (1) AR119158A1 (enExample)
AU (1) AU2020293614B2 (enExample)
BR (1) BR112021024664A2 (enExample)
CA (1) CA3142218A1 (enExample)
CL (2) CL2021003244A1 (enExample)
DK (1) DK3982960T3 (enExample)
EA (1) EA202193019A1 (enExample)
ES (1) ES2956471T3 (enExample)
FI (1) FI3982960T3 (enExample)
GB (1) GB201910116D0 (enExample)
HR (1) HRP20230696T1 (enExample)
HU (1) HUE063163T2 (enExample)
IL (1) IL288615A (enExample)
LT (1) LT3982960T (enExample)
MA (1) MA56187B1 (enExample)
MD (1) MD3982960T2 (enExample)
MX (1) MX2021014557A (enExample)
MY (1) MY205687A (enExample)
PH (1) PH12021552966A1 (enExample)
PL (1) PL3982960T3 (enExample)
PT (1) PT3982960T (enExample)
RS (1) RS64412B1 (enExample)
SG (1) SG11202113304YA (enExample)
SI (1) SI3982960T1 (enExample)
SM (1) SMT202300261T1 (enExample)
TW (1) TW202112370A (enExample)
UA (1) UA129869C2 (enExample)
WO (1) WO2020249977A1 (enExample)
ZA (1) ZA202110685B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2022084693A1 (en) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
WO2022172006A1 (en) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
SI4288036T1 (sl) 2022-04-27 2024-10-30 Kalvista Pharmaceuticals Limited Formulacije zaviralca plazemskega kalikreina
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (en) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PT3305778T (pt) 2013-05-23 2022-05-02 Kalvista Pharmaceuticals Ltd Inibidores de calicreína plasmática
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Also Published As

Publication number Publication date
CL2023000639A1 (es) 2023-10-30
DK3982960T3 (da) 2023-08-21
US20220218680A1 (en) 2022-07-14
JP2025124716A (ja) 2025-08-26
LT3982960T (lt) 2023-08-25
JP7688078B2 (ja) 2025-06-03
ES2956471T3 (es) 2023-12-21
AU2020293614A1 (en) 2022-01-27
BR112021024664A2 (pt) 2022-05-31
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
EP3982960A1 (en) 2022-04-20
PL3982960T3 (pl) 2024-01-15
JP2023166406A (ja) 2023-11-21
EA202193019A1 (ru) 2022-03-24
SMT202300261T1 (it) 2023-09-06
MA56187A (fr) 2022-04-20
RS64412B1 (sr) 2023-09-29
IL288615A (en) 2022-02-01
SI3982960T1 (sl) 2023-10-30
CL2021003244A1 (es) 2022-09-30
FI3982960T3 (fi) 2023-08-29
JP7356518B2 (ja) 2023-10-04
AU2020293614B2 (en) 2024-08-15
MY205687A (en) 2024-11-06
MD3982960T2 (ro) 2023-12-31
EP4282474A3 (en) 2024-02-14
CA3142218A1 (en) 2020-12-17
CN114126612A (zh) 2022-03-01
MX2021014557A (es) 2022-01-11
ZA202110685B (en) 2024-06-26
KR102748728B1 (ko) 2024-12-30
SG11202113304YA (en) 2021-12-30
KR20220024220A (ko) 2022-03-03
TW202112370A (zh) 2021-04-01
UA129869C2 (uk) 2025-08-27
GB201910116D0 (en) 2019-08-28
PH12021552966A1 (en) 2022-07-25
MA56187B1 (fr) 2023-09-27
NZ782935A (en) 2025-02-28
JP2022536287A (ja) 2022-08-15
AR119158A1 (es) 2021-12-01
HRP20230696T1 (hr) 2023-10-13
WO2020249977A1 (en) 2020-12-17
HUE063163T2 (hu) 2023-12-28

Similar Documents

Publication Publication Date Title
IL288615A (en) Treatments for hereditary angioedema
IL288612A (en) Treatments for angioedema
SG11202109645QA (en) Methods of treating al amyloidosis
IL290756A (en) Treatment of azoles
IL289687A (en) Preparations for the treatment of hair loss
GB202006390D0 (en) Novel treatments
GB201918853D0 (en) Methods of treatment
EP3758702A4 (en) TREATMENT OF HEREDITARY ANGIOEDEMA
IL290983A (en) Treatment methods
HK40070597A (en) Treatments of angioedema
IL288526A (en) Therapies based on thiarbine and meters drug thiarbine
EP3110508A4 (en) Treatment of hereditary angioedema with c1 inhibitor
GB202116339D0 (en) Novel treatments
GB202112979D0 (en) Novel treatments
GB202112978D0 (en) Novel treatments
GB202112980D0 (en) Novel treatments
GB202112981D0 (en) Novel treatments
GB202112976D0 (en) Novel treatments
GB202112977D0 (en) Novel treatments
GB202109894D0 (en) Novel treatments
GB202109896D0 (en) Novel treatments
GB202109895D0 (en) Novel treatments
GB202103400D0 (en) Novel treatments
GB201917908D0 (en) Novel treatments
GB202101291D0 (en) Novel treatments